Court Blocks Israeli Co. From Suing Amgen

Law360, New York (January 30, 2007, 12:00 AM EST) -- Notching a win for Amgen Inc. in a protracted patent dispute over its arthritis drug Enbrel, a U.S. federal appeals court has found that an Israeli company cannot collect royalties on the treatment.

The U.S. Court of Appeals for the Federal Circuit ruled Monday that Israel Bio-Engineering Project (IBEP) did not have standing to bring a patent infringement suit against Amgen because it could not pin down the sole ownership of the patent.

On the surface, the disagreement involved a protein used to remedy rheumatoid arthritis...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.